Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06717698 · ClinicalTrials.gov registry record · Phase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

A Phase 2 study of Chronic Kidney Disease, sponsored by Novo Nordisk A/S.

Recruiting
Registry status
Phase 2
Development phase
465
Enrollment target
20
Study locations

NCT06717698: Recruiting Phase 2 study of Chronic Kidney Disease, sponsored by Novo Nordisk A/S.

NCT06717698 is a Phase 2 study of Chronic Kidney Disease that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 465 participants, below the 3,202-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06717698, a Phase 2 study of Chronic Kidney Disease, is actively recruiting participants, sponsored by Novo Nordisk A/S.

RECRUITING
Registry status
Phase 2
Development phase
465 participants
Enrollment target
20
Study locations

Study Summary

The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study will last for up to 43 weeks.

Primary Outcome

Measured as a ratio to baseline.

Conditions Studied

Chronic Kidney Disease

Interventions

  • DRUG Placebo
  • DRUG Semaglutide
  • DRUG NNC0519-0130

Study Locations (20)

Florida

  • Northeast Research Institute - Fleming Island
  • Encore Medical Research LLC - Hollywood
  • Northeast Research Institute - Saint Augustine
  • Clinical Research of Cent FL - Winter Haven

Texas

  • Davita Clinical Research - El Paso
  • Clinical Advancement Center - San Antonio
  • Tekton Research - San Antonio

California

  • N America Res Inst - San Dimas - San Dimas
  • NorCal Endocrinology and Internal Medicine - San Ramon

North Carolina

  • Carteret Medical Group - Morehead City
  • Brookview Hills Research Associates, LLC - Winston-Salem

Buenos Aires

  • Centro Médico CIMEL - Lanús Este
  • Renalida - Mar del Plata

Colorado

  • Rocky Mount Reg VA Med-DN - Aurora

Illinois

  • Endeavor Health - Skokie

Indiana

  • Velocity Clin. Res Valparaiso - Valparaiso

Trial Details

FieldValue
Enrollment Target 465 participants
Start Date 2024-12-02
Est. Completion 2026-09-17
Phase Phase 2
Novo Nordisk A/S

431 total trials

What NCT06717698 shows while recruiting

NCT06717698 is an interventional study that assigns participants to a tested intervention. The registered 465 participants enrollment target is mid-sized for trials with a published cap, below the 3,202-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06717698 names 20 study sites across 12 states, led by Florida, Texas, California.

Frequently Asked Questions

What is clinical trial NCT06717698 about?

NCT06717698 is a clinical study titled "A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease". The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NN...

What is the current status of trial NCT06717698?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 465 participants. The study started on 2024-12-02. Estimated completion is 2026-09-17.

What conditions does trial NCT06717698 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT06717698?

The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), NNC0519-0130 (DRUG).

Who is sponsoring clinical trial NCT06717698?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06717698 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06717698's enrollment target sits among peer trials

465 27th of 101 higher than 75 of 101 other Chronic Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07420283 · 465 participants · Phase 2

    A Study of Brenipatide in Participants With Opioid Use Disorder

  • NCT05312879 · 466 participants · Phase 2

    Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

  • NCT06917404 · 466 participants · Phase 3

    A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

  • NCT07055165 · 466 participants · NA

    Connect2Care: Prostate Cancer Education and Screenings for African American Men

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06717698

Source: ClinicalTrials.gov NCT06717698, the US trial registry maintained by the National Library of Medicine. NCT06717698 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.